Key takeaways
- AppLovin, ADMA and Krispy Kreme posted large intraday gains following company reports, while semiconductor selling intensified.
- The morning outlook identified several of these dividing lines, but Thursday’s winners do not establish a broad industry rally or validate a forecasting model.
- Positive prior-close sentiment offered context; individual earnings, margins and financing exposure still decided the outcome.
Thursday is delivering a sharp divide between company-level winners and a falling technology benchmark. Around 11:22–11:23 a.m. ET on November 5, AppLovin was up 29.53%, Xeris Biopharma 26.58%, ADMA Biologics 25.00% and Krispy Kreme 30.48%, against Wednesday’s regular-session closes. These are intraday moves, not closing returns; later prices can differ.
The pattern partly follows the morning industry outlook: chip weakness, selected software earnings strength and a solar rebound. It also exposes the limits of treating industry membership as a sufficient reason to buy.
What the morning assessment got into focus
The November 5 sentiment assessment used November 4 completed prices. Its semiconductor score was only 13.0/100 and AI infrastructure and hardware 16.1, both very negative. Healthcare scored 76.4, consumer, retail and leisure 74.7, utilities 70.0 and software 62.2; the overall reading was neutral at 48.0.
Those price-derived readings describe the starting conditions. They are not probabilities that every constituent will rise. The regular session strengthened the semiconductor warning: Qualcomm fell 11.41% and Nvidia 6.77% around 11:22–11:23 a.m. ET, according to Nasdaq’s stock quotations.
AppLovin’s advance strengthened the selected-software thesis. EPAM, up 15.89%, added another technology-services winner, although the platform groups it under Cloud Infrastructure & Cybersecurity. That distinction matters: gains across several businesses cannot be relabelled as one industry’s measured index return.
Earnings explain the exceptional moves
AppLovin’s third-quarter release reported $2.185 billion of revenue, up 55%, and $1.439 billion of net income. Management’s $2.365 billion–$2.395 billion fourth-quarter revenue range is guidance, still to be delivered. Investors were rewarding advertising execution despite weakness elsewhere in technology.
ADMA’s November 4 results showed revenue up 5% to $141.1 million, but net income up 37% to $49.9 million. Gross margin reached 71%, compared with 56% a year earlier. Its reaction illustrates why earnings quality can matter more than the headline sales-growth rate.
Xeris’s gain supplied another biotech standout. Warby Parker rose 24.59%, extending strength into a different business model. The platform classifies Xeris and ADMA as Biotechnology and Warby Parker as Healthcare & Pharmaceuticals. These related groups should remain separate when assessing breadth.
The advance reached selected financial and leisure businesses too: Encore Capital gained 14.67%, Corpay 8.97%, Toyota 10.30% and United Parks & Resorts 6.90%. These examples broaden the list of winners beyond software and healthcare, without demonstrating that their entire industries rose.
Krispy Kreme’s Thursday report raised annual revenue guidance to $1.35 billion–$1.40 billion. Yet quarterly revenue declined 12.4% to $328.8 million, reflecting refranchising, and the company still reported a $13.3 million GAAP loss. Its rally expresses improving turnaround expectations, not proof that consumer demand is uniformly strong.
Where the optimistic interpretation breaks down
Sunrun was up 5.80% around 11:23 a.m. ET, versus roughly 15% in the earlier premarket analysis. Both comparisons use the preceding close; the smaller regular-session gain shows why an overnight move should not be assumed to persist.
The Real-Money Portfolio’s current published holdings, dated October 31, offer further counterexamples. Solaris Energy Infrastructure fell 4.25%, Enerpac 4.43% and Replimune 4.45%. Solaris provides power-generation exposure; Enerpac is an industrial-equipment business; Replimune carries company-specific clinical and regulatory risk. Their declines challenge any assumption that power, industrials or biotech automatically share the day’s strongest returns. These are individual stock moves, not a calculation of the portfolio’s return.
What to watch next
The next test is whether earnings winners retain support as selling pressure spreads or eases. Broader participation, repeatable revenue and cash conversion would make the rotation more durable. Profit-taking, funding costs and disappointing follow-through could reverse it.
Thursday supports selective earnings-led rotation and the morning caution on chips. It does not yet establish a market-wide recovery.
Research only, not investment advice.